세계의 액티빈 A : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)

The global market for Activin A was estimated to be worth US$ 20.53 million in 2024 and is forecast to a readjusted size of US$ 47.34 million by 2031 with a CAGR of 12.5% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Activin A cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Activins, members of the TGF-beta superfamily, are disulfide-linked dimeric proteins originally purified from gonadal fluids as proteins that stimulated pituitary follicle stimulating hormone (FSH) release. Activin proteins have a wide range of biological activities, including mesoderm induction, neural cell differentiation, bone remodeling, hematopoiesis and roles in reproductive physiology. Activin isoforms and other members of the TGF-beta superfamily exert their biological effects by binding to heteromeric complexes of a type I and a type II serine-threonine kinase receptor, both of which are essential for signal transduction.In 2024, global Activin A production reached approximately 1115 mg, with an average global market price of around 18.4 USD/µg

With the rising incidence of cancers, fibrotic disorders, and reproductive / endocrine health issues such as PCOS or infertility, there is sharply increasing demand for novel diagnostic markers and therapeutic targets. Activin A's central role in cellular signaling, immune modulation and tissue remodeling is drawing heightened attention from biopharma and academic researchers. In addition, the rise of regenerative medicine and stem cell therapies fuels demand for factors that can regulate stem cell fate and tissue repair, among which Activin A is prominent. Biotechnology innovations-improvements in recombinant expression systems, purification and stability enhancements, as well as delivery system optimization-are reducing production costs and risks of quality, enabling broader application from only high-end research to diagnostics and therapeutic products. Government and regulatory policies in many countries supporting biomarkers and precision medicine, along with public funding, further release opportunities for market growth.

Despite many opportunities, the Activin A market faces notable risks. First, the biological mechanisms of Activin A are complex and highly context-dependent: its effects may be beneficial or harmful depending on disease state, dose, timing and tissue, which complicates therapeutic designs of neutralizing agents or antagonists and raises safety/efficacy uncertainties. Second, the R&D to clinical clinical trial path is long and expensive; proving efficacy and safety in specific indications in animal models and humans requires substantial investment in time and money, which is a barrier especially for smaller firms. Third, regulatory approval pathways vary widely across geographies: quality, safety, delivery format, combination therapies, and biomarker validation are addressed differently, and changes or delays in regulation can lengthen time to market. Also, competition is intensifying among established biotech / pharmaceutical companies, academic labs, and startups; differentiation, intellectual property protection, and effective commercialization strategies become critical.

Downstream demand is shifting from purely research reagents toward combined diagnostics + therapeutics. Research institutions continue to purchase Activin A proteins, antibodies, and assay kits, but diagnostic laboratories and clinical settings are increasingly adopting Activin A as a biomarker for early disease detection (cancer, fibrosis, inflammatory diseases). Biopharma firms are progressing therapeutic development targeting Activin A (neutralizing antibodies, receptor antagonists) in indication areas such as antifibrosis, tumor suppression, and enhancing tissue regeneration. Precision medicine / personalized therapeutic strategies are favoring monitoring of Activin A levels or activity for patient stratification. Geographically, emerging regions (Asia, Latin America, Middle East) are increasing their investment in health research infrastructure, so demand growth in Activin A-related products is accelerating there relative to mature markets

Upstream raw inputs include recombinant Activin A expression systems (e.g. bacterial, yeast, mammalian cell lines), culture media and components, purification media and buffers, stability enhancers, QC reagents and analytical assays, antibodies or antagonists for neutralization, etc. A single-line capacity refers to a full production line from expression -> purification -> quality control -> formulation/stability (liquid / freeze-dried) -> packaging & distribution. Within such a line, expression system choice and correct folding / modification are key bottlenecks; purification and removal of endotoxins or unintended impurities are demanding; QC including bioactivity assays and safety validations determine whether outputs meet clinical-grade or just research-grade standards. Research reagent / ELISA-level Activin A products have shorter lead times and lower investment for single-line deployment; but therapeutic products-especially neutralizing antibodies, receptor antagonists, or those delivered via novel delivery systems-require much larger capital, facilities, skilled personnel, and longer development & validation times.

This report aims to provide a comprehensive presentation of the global market for Activin A, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Activin A by region & country, by Type, and by Application.

The Activin A market size, estimations, and forecasts are provided in terms of sales volume (mg) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Activin A.

Market Segmentation

By Company

• Merck Millipore
• Thermo Fisher Scientific
• Bio-Techne
• StemRD
• Prospec
• Proteintech Group
• Ajinomoto
• Enzo Life Sciences
• IBL
• STEMCELL
• Sino Biological
• PeproTech
• ReproCELL

Segment by Type

• Activin-A Human
• Activin-A Mouse (Rat)

Segment by Application

• Commercial Research
• Academic Research

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Activin A manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Activin A in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Activin A in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Activin A Product Introduction
• 1.2 Global Activin A Market Size Forecast
  • 1.2.1 Global Activin A Sales Value (2020-2031)
  • 1.2.2 Global Activin A Sales Volume (2020-2031)
  • 1.2.3 Global Activin A Sales Price (2020-2031)
• 1.3 Activin A Market Trends & Drivers
  • 1.3.1 Activin A Industry Trends
  • 1.3.2 Activin A Market Drivers & Opportunity
  • 1.3.3 Activin A Market Challenges
  • 1.3.4 Activin A Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Activin A Players Revenue Ranking (2024)
• 2.2 Global Activin A Revenue by Company (2020-2025)
• 2.3 Global Activin A Players Sales Volume Ranking (2024)
• 2.4 Global Activin A Sales Volume by Company Players (2020-2025)
• 2.5 Global Activin A Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Activin A Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Activin A Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Activin A
• 2.9 Activin A Market Competitive Analysis
  • 2.9.1 Activin A Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Activin A Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Activin A as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Activin-A Human
  • 3.1.2 Activin-A Mouse (Rat)
• 3.2 Global Activin A Sales Value by Type
  • 3.2.1 Global Activin A Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Activin A Sales Value, by Type (2020-2031)
  • 3.2.3 Global Activin A Sales Value, by Type (%) (2020-2031)
• 3.3 Global Activin A Sales Volume by Type
  • 3.3.1 Global Activin A Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Activin A Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Activin A Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Activin A Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Commercial Research
  • 4.1.2 Academic Research
• 4.2 Global Activin A Sales Value by Application
  • 4.2.1 Global Activin A Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Activin A Sales Value, by Application (2020-2031)
  • 4.2.3 Global Activin A Sales Value, by Application (%) (2020-2031)
• 4.3 Global Activin A Sales Volume by Application
  • 4.3.1 Global Activin A Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Activin A Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Activin A Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Activin A Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Activin A Sales Value by Region
  • 5.1.1 Global Activin A Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Activin A Sales Value by Region (2020-2025)
  • 5.1.3 Global Activin A Sales Value by Region (2026-2031)
  • 5.1.4 Global Activin A Sales Value by Region (%), (2020-2031)
• 5.2 Global Activin A Sales Volume by Region
  • 5.2.1 Global Activin A Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Activin A Sales Volume by Region (2020-2025)
  • 5.2.3 Global Activin A Sales Volume by Region (2026-2031)
  • 5.2.4 Global Activin A Sales Volume by Region (%), (2020-2031)
• 5.3 Global Activin A Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Activin A Sales Value, 2020-2031
  • 5.4.2 North America Activin A Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Activin A Sales Value, 2020-2031
  • 5.5.2 Europe Activin A Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Activin A Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Activin A Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Activin A Sales Value, 2020-2031
  • 5.7.2 South America Activin A Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Activin A Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Activin A Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Activin A Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Activin A Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Activin A Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Activin A Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Activin A Sales Value, 2020-2031
  • 6.3.2 United States Activin A Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Activin A Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Activin A Sales Value, 2020-2031
  • 6.4.2 Europe Activin A Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Activin A Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Activin A Sales Value, 2020-2031
  • 6.5.2 China Activin A Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Activin A Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Activin A Sales Value, 2020-2031
  • 6.6.2 Japan Activin A Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Activin A Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Activin A Sales Value, 2020-2031
  • 6.7.2 South Korea Activin A Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Activin A Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Activin A Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Activin A Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Activin A Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Activin A Sales Value, 2020-2031
  • 6.9.2 India Activin A Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Activin A Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Merck Millipore
  • 7.1.1 Merck Millipore Company Information
  • 7.1.2 Merck Millipore Introduction and Business Overview
  • 7.1.3 Merck Millipore Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Merck Millipore Activin A Product Offerings
  • 7.1.5 Merck Millipore Recent Development
• 7.2 Thermo Fisher Scientific
  • 7.2.1 Thermo Fisher Scientific Company Information
  • 7.2.2 Thermo Fisher Scientific Introduction and Business Overview
  • 7.2.3 Thermo Fisher Scientific Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Thermo Fisher Scientific Activin A Product Offerings
  • 7.2.5 Thermo Fisher Scientific Recent Development
• 7.3 Bio-Techne
  • 7.3.1 Bio-Techne Company Information
  • 7.3.2 Bio-Techne Introduction and Business Overview
  • 7.3.3 Bio-Techne Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Bio-Techne Activin A Product Offerings
  • 7.3.5 Bio-Techne Recent Development
• 7.4 StemRD
  • 7.4.1 StemRD Company Information
  • 7.4.2 StemRD Introduction and Business Overview
  • 7.4.3 StemRD Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 StemRD Activin A Product Offerings
  • 7.4.5 StemRD Recent Development
• 7.5 Prospec
  • 7.5.1 Prospec Company Information
  • 7.5.2 Prospec Introduction and Business Overview
  • 7.5.3 Prospec Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Prospec Activin A Product Offerings
  • 7.5.5 Prospec Recent Development
• 7.6 Proteintech Group
  • 7.6.1 Proteintech Group Company Information
  • 7.6.2 Proteintech Group Introduction and Business Overview
  • 7.6.3 Proteintech Group Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Proteintech Group Activin A Product Offerings
  • 7.6.5 Proteintech Group Recent Development
• 7.7 Ajinomoto
  • 7.7.1 Ajinomoto Company Information
  • 7.7.2 Ajinomoto Introduction and Business Overview
  • 7.7.3 Ajinomoto Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Ajinomoto Activin A Product Offerings
  • 7.7.5 Ajinomoto Recent Development
• 7.8 Enzo Life Sciences
  • 7.8.1 Enzo Life Sciences Company Information
  • 7.8.2 Enzo Life Sciences Introduction and Business Overview
  • 7.8.3 Enzo Life Sciences Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Enzo Life Sciences Activin A Product Offerings
  • 7.8.5 Enzo Life Sciences Recent Development
• 7.9 IBL
  • 7.9.1 IBL Company Information
  • 7.9.2 IBL Introduction and Business Overview
  • 7.9.3 IBL Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 IBL Activin A Product Offerings
  • 7.9.5 IBL Recent Development
• 7.10 STEMCELL
  • 7.10.1 STEMCELL Company Information
  • 7.10.2 STEMCELL Introduction and Business Overview
  • 7.10.3 STEMCELL Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 STEMCELL Activin A Product Offerings
  • 7.10.5 STEMCELL Recent Development
• 7.11 Sino Biological
  • 7.11.1 Sino Biological Company Information
  • 7.11.2 Sino Biological Introduction and Business Overview
  • 7.11.3 Sino Biological Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Sino Biological Activin A Product Offerings
  • 7.11.5 Sino Biological Recent Development
• 7.12 PeproTech
  • 7.12.1 PeproTech Company Information
  • 7.12.2 PeproTech Introduction and Business Overview
  • 7.12.3 PeproTech Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 PeproTech Activin A Product Offerings
  • 7.12.5 PeproTech Recent Development
• 7.13 ReproCELL
  • 7.13.1 ReproCELL Company Information
  • 7.13.2 ReproCELL Introduction and Business Overview
  • 7.13.3 ReproCELL Activin A Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 ReproCELL Activin A Product Offerings
  • 7.13.5 ReproCELL Recent Development

8 Industry Chain Analysis

• 8.1 Activin A Industrial Chain
• 8.2 Activin A Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Activin A Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Activin A Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer